Patents by Inventor Jules Chen
Jules Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240070512Abstract: A quantum computing system and method are disclosed. The system includes a modular architecture comprising a plurality of units, each unit having an input interface and an output interface and having a type selected from a set including a controller unit, a quantum processing unit and a classical processing unit. Each quantum processing unit is connectable to a quantum computing device and includes a data converter, the input interface being selectively connectable to other units of the modular architecture and configured to pass data received at the input interface to the data converter and pass the output of the data converter to the quantum computing device, the output interface being selectively connectable to other units of the modular architecture and configured to pass data received from the quantum computing device to the data converter and pass the output of the data converter to the output interface for communication to the units of the modular architecture connected to the output interface.Type: ApplicationFiled: January 14, 2022Publication date: February 29, 2024Inventors: Shuxiang Cao, Hongxiang Chen, Edward Grant, Jules Tilly
-
Publication number: 20230279513Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: January 13, 2023Publication date: September 7, 2023Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Publication number: 20230235412Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.Type: ApplicationFiled: November 14, 2022Publication date: July 27, 2023Inventors: Michelle M. Tabb, Ming-Chou Lee, Lilly I. Kong, Ning Lu, Michael Aye, Fan Chen, Jules Chen
-
Patent number: 11555223Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: GrantFiled: October 5, 2020Date of Patent: January 17, 2023Assignee: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 11499199Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.Type: GrantFiled: October 29, 2019Date of Patent: November 15, 2022Assignee: Quest Diagnostics Investments LLCInventors: Michelle M. Tabb, Ming-Chou Lee, Lilly I. Kong, Ning Lu, Michael Aye, Fan Chen, Jules Chen
-
Publication number: 20210095352Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: October 5, 2020Publication date: April 1, 2021Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 10801078Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: GrantFiled: August 22, 2017Date of Patent: October 13, 2020Assignee: Quest Diagnostics Infectious Disease, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Patent number: 10793924Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: GrantFiled: June 2, 2017Date of Patent: October 6, 2020Assignee: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Publication number: 20200123596Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.Type: ApplicationFiled: October 29, 2019Publication date: April 23, 2020Applicant: Quest Diagnostics Investments LLCInventors: Michelle M. Tabb, Ming-Chou Lee, Lilly I. Kong, Ning Lu, Michael Aye, Fan Chen, Jules Chen
-
Publication number: 20190382826Abstract: The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment, with therapeutic agents that inhibit Bordetella holmesii. These methods are based on detecting Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS 1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: March 23, 2017Publication date: December 19, 2019Applicant: Quest Diagnostics Investments LLCInventors: Jules Chen, Michelle Tabb
-
Patent number: 10465252Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.Type: GrantFiled: May 7, 2008Date of Patent: November 5, 2019Assignee: Quest Diagnostics Investments IncorporatedInventors: Michelle M. Tabb, Ming-Chou Lee, Lilly I. Kong, Ning Lu, Michael Aye, Fan Chen, Jules Chen
-
Publication number: 20190211408Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: June 2, 2017Publication date: July 11, 2019Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Patent number: 10260113Abstract: The present invention generally relates to a molecular test of Influenza A, Influenza B, Respiratory Syncytial Virus A, and Respiratory Syncytial Virus B in order to identify patients with a viral infection. Accordingly methods and compositions are disclosed to determine the presence or absence of a viral pathogen in a sample containing one or more target nucleic acids from the M gene of Influenza A, Influenza B, Respiratory Syncytial Virus A, and/or Respiratory Syncytial Virus B.Type: GrantFiled: December 11, 2012Date of Patent: April 16, 2019Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Jules Chen, Lilly I. Kong, Ming-Chou Lee, Fan Chen, Michelle M. Tabb, Michael Aye
-
Publication number: 20180044742Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: ApplicationFiled: August 22, 2017Publication date: February 15, 2018Applicant: Focus Diagnostics, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Patent number: 9745638Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: GrantFiled: April 29, 2014Date of Patent: August 29, 2017Assignee: Focus Diagnostics, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Patent number: 9194006Abstract: Provided herein are methods for identifying the presence or absence of a target nucleic acid from a microorganism using direct amplification without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids.Type: GrantFiled: July 6, 2012Date of Patent: November 24, 2015Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Maurice Exner, Luca Jacky, Yin-Peng Chen, Huong Mai, Jules Chen, Michelle M. Tabb, Michael Aye, Emberlee Eleazar
-
Publication number: 20140349275Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: ApplicationFiled: April 29, 2014Publication date: November 27, 2014Applicant: Focus Diagnostics, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Patent number: 8748092Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: GrantFiled: January 12, 2011Date of Patent: June 10, 2014Assignee: Focus Diagnostics, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Publication number: 20130022963Abstract: Provided herein are methods for identifying the presence or absence of a target nucleic acid from a microorganism using direct amplification without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids.Type: ApplicationFiled: July 6, 2012Publication date: January 24, 2013Inventors: MAURICE EXNER, LUCA JACKY, YIN-PENG CHEN, HUONG MAI, JULES CHEN, MICHELLE M. TABB, MICHAEL AYE, EMBERLEE ELEAZAR
-
Patent number: 8354230Abstract: The present invention generally relates to a molecular test of Influenza A, Influenza B, Respiratory Syncytial Virus A, and Respiratory Syncytial Virus B in order to identify patients with a viral infection. Accordingly methods and compositions are disclosed to determine the presence or absence of a viral pathogen in a sample containing one or more target nucleic acids from the M gene of Influenza A, Influenza B, Respiratory Syncytial Virus A, and/or Respiratory Syncytial Virus B.Type: GrantFiled: December 21, 2007Date of Patent: January 15, 2013Assignee: Quest Diagnostics Investments Inc.Inventors: Jules Chen, Lilly I. Kong, Ming-Chou Lee, Fan Chen, Michelle M. Tabb, Michael Aye